Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin (Nasdaq: AMRN) is rebounding following an earlier dip on news that its Vascepa wasn't in the FDA Orange Book for April.
To go to the FDA's Orange Book website, click here.
Shares are down 0.5 percent Friday.
To go to the FDA's Orange Book website, click here.
Shares are down 0.5 percent Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Reinstates Amarin Corporation (AMRN) at Underweight
- Jannik Sinner says he will not compete at US Open due to injury
- Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
